MarketResearchReports.com: PharmaSphere: Asia Pacific Deal Trends, 2004-2013, New Report Launched

PharmaSphere: Asia Pacific Deal Trends, 2004-2013 report offers an in-depth understanding of the key deals that took place in the region during the last decade. The type of deals covered in the report include Mergers & Acquisitions (M&A), Licensing and Collaboration & Partnerships. The report also provides understanding on the regional differences in the deal making activity to that of the global trends and key trends are outlined with insight on drivers such as regulatory policy, macro-economic and industry factors as well as market access challenges. Case studies including the top deals in value among Mergers & Acquisition, Licensing and Collaboration & Partnerships are strategically analyzed to provide comprehensive understanding on areas such as structure and status of the deal vis a vis the overall corporate strategy.

The report is an essential source of information and analysis on strategic deals in the Asia Pacific region. It includes top players in the global and regional pharmaceuticals and healthcare market. Using detailed company data and financial analysis, publisher has highlighted certain deals in the pharmaceutical market, forming a basis for in-depth analysis of the factors driving deal-making in the industry, currently and into the future. The report discusses the key factors shaping and driving the pharmaceutical industry in the Asia Pacific region, and provides insight on the competitive landscape and emerging strategies that are expected to significantly alter the market position of industry leaders.

Key Questions Answered

• How are the main deal categories faring among top countries in the Asia Pacific region over the past decade?
• What are the primary reasons for increased activity in strategic deals by leading pharmaceutical companies in APAC region?
• What are the key trends, and strategies involved in M&As, licensing deals, and collaboration agreements entered into by leading pharmaceutical and healthcare companies in the Asia Pacific region?
• What strategies are the most successful companies pursuing to gain and maintain their market leading position?

Scope

• In-depth understanding of the key pharmaceutical and healthcare deals that took place in the APAC region during the last decade. Furthermore, key deals are discussed from a domestic and global point of view
• Current regulatory framework in various markets in APAC including recent and/or ongoing developments that are expected to impact or influencing the industry are discussed
• Dealmaking strategies: insightful analysis on the terms, strategic implications and synergies of recent -deals activity in the APAC pharmaceutical industry
• Collaboration and acquisition strategies: exhaustive discussion on the strategic implications and synergies of recent M&A and partnering activities
• Expert insights on the corporate strategies of various drug companies seeking a competitive advantage in the pharmaceutical market place
• Case studies on top deal making activities shedding light on rationale and strategy.

Reasons to buy

• Understand the primary drivers behind major deal initiatives in the APAC region.
• Analyze the structures of the deal and gain insight on the various factors considered when structuring deal terms in strategic acquisitions, mergers, collaborations, and licensing.
• Identify rationale behind potential takeover targets and partners, thereby maximizing your opportunities for consolidation, investment, and strategic partnerships in the Asia Pacific region.
• Use this information as an independent source for your due diligence and transaction strategy.

Spanning over 71 pages, 22 tables and 7 figures, “PharmaSphere: Asia Pacific Deal Trends, 2004–2013” report provides information on market overview, drivers and challenge, competition and key trends.

In addition to covering the Historical Dealmaking Trends, Mergers and Acquisitions, Licensing Arrangements, Collaborations and Partnerships, Future Outlook, Case Studies.

Find all Pharma and Healthcare market research reports under a single page.

MarketResearchReports.com: Mobile Healthcare (mHealth) revenue to reach $9 billion in 2014, finds new report

As healthcare providers seek to maximize their patient outreach while minimizing costs, many view mobile healthcare (or mHealth) as the solution to improve healthcare cost-efficiency. mHealth refers to the usage of mobile communications technology & devices to enhance access to healthcare information, improve distribution of routine and emergency health services and provide diagnostic services.

Mobile network operators also view mHealth as a lucrative opportunity for the monetization of their mobile connectivity services. Given that most operators have established themselves as reputable consumer brands, they are also eyeing on opportunities to offer services beyond simple connectivity. Many operators already offer branded or co-branded end-to-end mHealth solutions to their customer bases.

In addition, mHealth offers a multitude to opportunities to the pharmaceutical industry ranging from R&D activities to securing the supply chain and, in the battle against counterfeit drugs.

Driven by the thriving ecosystem, the research estimates that the mHealth market will account for nearly $9 Billion in 2014 alone. Despite barriers relating to regulation, patient acceptance and privacy concerns, research estimates further growth at a CAGR of nearly 40% over the next 6 years.

"The Mobile Healthcare (mHealth) Bible: 2014 - 2020" report presents an in-depth assessment of the global mHealth market. In addition to covering key market drivers, challenges, future roadmap, value chain analysis, deployment case studies, service/product strategies and strategic recommendations, the report also presents comprehensive forecasts for the mHealth market from 2013 till 2020. Historical revenue figures for 2010 – 2012 are also presented. The forecasts and historical revenue figures are individually segmented for 5 individual submarkets, 29 use case categories, 5 ecosystem player categories, 6 geographical regions and 34 countries.

The report will be of value to current and future potential investors into the mHealth sector, as well as mobile network operators, healthcare service providers, pharmaceutical companies, healthcare insurers, government healthcare institutions, infrastructure/device vendors, application developers and software/service vendors who wish to broaden their knowledge of the mHealth ecosystem. Spanning over 234 pages, 103 tables and figures, this report provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics.

Find all  IT and e-health market research reports under a single page.

MarketResearchReports.com: MediFocus: Future of Molecular Imaging, New Report Launched

Molecular imaging is at the frontier of diagnostic imaging. It is a vast and multi-disciplinary field that consists of a range of techniques, allowing imaging of various organs and sites within the body with specific targeted probes. Molecular imaging can be defined as ‘’the visualization, characterization and measurement of biological processes at the molecular and cellular levels in human and other living systems’’. Although sluggish economic growth has hindered the growth of the molecular imaging market right from its inception in the leading economies of the world such as in the United States and Europe, the market has attracted attention from both academia and manufacturers in recent years. The need for less invasive imaging techniques and more specific imaging probes has fuelled continued development and ever-changing market competition with molecular imaging.

MediFocus: Future of Molecular Imaging report offers a comprehensive analysis of the molecular imaging market, including new imaging techniques and late-stage imaging probes. Included within is an analysis of companies currently active in the field with their commercial positioning and portfolio assessment. The report identifies and evaluates key trends and advances shaping the global molecular imaging market, highlighting testimonials from top physicians around the world. This report was built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by publisher team of diagnostic imaging experts.

Scope

• An overview of the molecular imaging landscape
• Investigation of current and future market competition for molecular imaging
• Pipeline assessment with product profiles, SWOT analysis and commercial positioning
• Evaluation of technology trends in molecular imaging and physician perception
• Coverage of key market players with portfolio assessment and SWOT analysis
• Direct quotes from Key Opinion Leaders (KOL) currently using and developing molecular imaging probes

Reasons to buy

• Understand the trends shaping and driving the molecular imaging markets
• Drive revenues, formulate effective sales and marketing strategies, and gain in-depth understanding of the competitive landscape
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition
• Take a comprehensive look at the market’s late-stage probe pipeline and identify promising, paradigm-shifting products
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth
• What’s the next big thing in the global molecular imaging market? Identify, understand and capitalize

Spanning over 184 pages, 71 tables and 26 figures, “ MediFocus: Future of Molecular Imaging ” report provides insight into the market opportunities, barriers and drivers within the market for the benefit of new companies willing to enter this market in the near future. Find all Pharma and Healthcare Market Research Reports under a single page.

In addition to covering the Overview, Unmet Needs Analysis, Market Opportunity Analysis, Market Drivers and Barriers, Imaging Probes Assessment, Probes Pipeline Assessment, Current and Future Players.  The report covers 13 companies; Navidea Biopharmaceuticals, Lantheus Medical Imaging, Mallinckrodt Pharmaceuticals, Avid Radiopharmaceuticals (Eli Lilly), Bracco Imaging, GE Healthcare, Piramal Imaging, Siemens, Novelos Therapeutics, Affibody, Atreus Pharmaceuticals, Kereos, Progenics Pharmac. Find all Medical devices market research reports under a single page.

MarketResearchReports.com: Telemedicine and M-Health Convergence Market to Reach $1.8 Trillion By 2019

Worldwide markets are poised to achieve significant growth as the telemedicine systems merge with the smart phone systems of engagement to provide a way to improve clinical care delivery to patients with chronic disease, decreasing hospitalizations and visits to the emergency room. There is a convergence of telemedicine and m-health as the patients become more responsible for their own care delivery and their own health.

According to the study telemedicine dedicated device and software markets at $843 million in 2012 are anticipated to reach $2.9 billion by 2019. M-Health markets related to telemedicine at $1.4 billion are anticipated to reach $1.5 trillion by 2019 due to the use of 7 billion smart phones and half that many connected tablet devices all over the world.

Clinical telemedicine services converge with m-health systems of engagement to lower cost of care and improve quality of care. Tele-medicine and M-health market driving forces relate to an overall trend toward ordinary people taking more responsibility for their own health. This trend has been more prevalent for women in the past 100 years than for men because women used to die very young and they had to learn how to keep themselves healthy. Women have been able to reverse this trend of dying young and to live longer than men in the past 40 years, illustrating that paying attention to health is important.

The cost of tele-medicine for the US veterans administration is $1,600 per patient per annum. This is substantially less than other NIC programs and nursing home care which can easily run to $100,000 per annum. VHA's experience is that an enterprise-wide home tele-medicine implementation is an appropriate and cost-effective way of managing chronic care patients in both urban and rural settings.

According to analyst of this report, “Differential diagnostic tools support differential telemedical treatment. The decision process take into account clinical findings form the home monitoring devices and from symptoms verbally communicated in a clinical services implementation.”

Analyst added, “Care delivery is enhanced by having clinicians be responsive to changes in patient condition that we know will lead to further patient deterioration if not treated immediately. A core part of responsible healthcare delivery is to use technology for healthcare reform. There is a focus on how to deliver care differently using telemedicine. No matter who pays for it, the use of telemedicine is anticipated to reduce the overall costs of healthcare delivery. Innovation is key to achieving improvements. For more information visit : Telemedicine and M-Health Convergence: Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2019

For long-term success, telehealth solutions require sustainable financing models. Investments in telehealth technologies foster sustainability by enabling productivity and efficiency gains and other improvements that can more than justify investment costs.

Both tele-medicine and m-health contribute to healthcare delivery in the home. M-health will surely be delivered over the smart phone. Tele-medicine is evolving toward smart phone device delivery as well.

Once FDA approved software runs on a tablet, people with an existing unit can download software and be equipped with a way to interact with the clinical service that performs monitoring. Long term, the services will be a very attractive part of telemonitoring.

Spanning over 879 pages, 299 tables and figures, this report provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics.

You can also visit our IT and e-health section:  IT and e-health Market Research Reports

MarketResearchReports.com: Prostate Cancer - Pipeline Review, H2 2013, New Report Launched

Prostate Cancer - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report also reviews key players involved in the therapeutic development for Prostate Cancer. Prostate Cancer - Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.

Scope

• A snapshot of the global therapeutic scenario for Prostate Cancer.
• A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Prostate Cancer pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Prostate Cancer.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 413 pages, 271 tables and 14 figures, “Prostate Cancer - Pipeline Review, H2 2013” report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects.

In addition to covering the Prostate Cancer Overview, Late Stage Products, Mid Clinical Stage Products, Early Clinical Stage Products, Discovery and Pre-Clinical Stage Products, Companies Involved in Prostate Cancer Therapeutics Development, Prostate Cancer Therapeutics - Drug Profile Updates, Prostate Cancer Therapeutics - Discontinued Products, Prostate Cancer Therapeutics - Dormant Products, Prostate Cancer - Product Development Milestones.  The report covers 185 companies; few are Bio-Path Holdings, Inc., ZIOPHARM Oncology, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Aphios Corporation, Astellas Pharma Inc., BioMarin Pharmaceutical Inc., GTx, Inc., Nippon Shinyaku Co., Ltd., Orion Corporation, Pfizer Inc., SuperGen, Inc., Anavex Life Sciences Corp., ValiRx Plc, Active Biotech AB, AEterna Zentaris Inc.

Find all Pharma & Healthcare Industry Reports under a single page at: Pharma and Healthcare Market Research Reports

MarketResearchReports.com: Hepatitis C - Pipeline Review, H2 2013, New Report Launched

Hepatitis C - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report also reviews key players involved in the therapeutic development for Hepatitis C. Hepatitis C - Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.

Scope

• A snapshot of the global therapeutic scenario for Hepatitis C.
• A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Hepatitis C pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Hepatitis C.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 291 pages, 177 tables and 14 figures, “ Hepatitis C - Pipeline Review, H2 2013 ” report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects.

In addition to covering the Hepatitis C Overview, Hepatitis C Therapeutics under Development by Companies, Hepatitis C Therapeutics under Investigation by Universities/Institutes, Late Stage Products, Mid Clinical Stage Products, Early Clinical Stage Products, Discovery and Pre-Clinical Stage Products, Companies Involved in Hepatitis C Therapeutics Development, Hepatitis C Therapeutics - Drug Profile Updates, Hepatitis C Therapeutics - Discontinued Products, Hepatitis C Therapeutics - Dormant Products, Hepatitis C - Product Development Milestones. The report covers 121 companies; few are Raptor Pharmaceuticals Corp., NeuroVive Pharmaceutical AB, Intas Pharmaceuticals Ltd., Digna Biotech, S.L., Debiopharm Group, Functional Genetics, Inc., StemCells, Inc., SCYNEXIS, Inc., Nutri Pharma ASA, Imgenex Corp., ImmunoBiology Limited, Altor BioScience Corporation, Anacor Pharmaceuticals, Inc., Pt. Bio Farma. Find all: Diseases Market Research Reports

MarketResearchReports.com: Rheumatoid Arthritis - Pipeline Review, H2 2013, New Report Launched

Rheumatoid Arthritis - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Rheumatoid Arthritis - Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.

Scope

• A snapshot of the global therapeutic scenario for Rheumatoid Arthritis.
• A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 392 pages, 277 tables and 14 figures, “Rheumatoid Arthritis - Pipeline Review, H2 2013” report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects.

In addition to covering the Rheumatoid Arthritis Overview, Rheumatoid Arthritis Therapeutics under Development by Companies, Rheumatoid Arthritis Therapeutics under Investigation by Universities/Institutes, Drug Profiles, Rheumatoid Arthritis Therapeutics - Drug Profile Updates, Rheumatoid Arthritis Therapeutics - Discontinued Products, Rheumatoid Arthritis Therapeutics - Dormant Products, Rheumatoid Arthritis - Product Development Milestones.  The report covers 201 companies; few are Alcon, Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Biogen Idec Inc., Amgen Inc., Antares Pharma, Inc., AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc, Inovio Biomedical Corporation. Find all: Healthcare Market Research Reports

MarketResearchReports.com: Non-Small Cell Lung Cancer - Pipeline Review, H2 2013, New Report Launched

Non-Small Cell Lung Cancer - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer. Non-Small Cell Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from publisher  proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team. 

Scope

• A snapshot of the global therapeutic scenario for Non-Small Cell Lung Cancer.
• A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 447 pages, 234 tables and 14 figures, “Non-Small Cell Lung Cancer - Pipeline Review, H2 2013”  report provides information on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects.

In addition to covering the Non-Small Cell Lung Cancer Overview, Non-Small Cell Lung Cancer Therapeutics under Development by Companies, Non-Small Cell Lung Cancer Therapeutics under Investigation by Universities/Institutes, Late Stage Products, Mid Clinical Stage Products, Early Clinical Stage Products, Discovery and Pre-Clinical Stage Products, Companies Involved in Non-Small Cell Lung Cancer Therapeutics Development, Non-Small Cell Lung Cancer Therapeutics - Drug Profile Updates, Non-Small Cell Lung Cancer Therapeutics - Discontinued Products, Non-Small Cell Lung Cancer Therapeutics - Dormant Products, Non-Small Cell Lung Cancer - Product Development Milestones.  The report covers 138 companies; few are Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Biogen Idec Inc., Shionogi & Co., Ltd., Amgen Inc., Sanofi-Aventis, AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc, Genentech, Inc., Nektar Therapeutics, Inovio Biomedical Corporation, MedImmune LLC.

Find all: Pharma and Healthcare Market Research Reports

MarketResearchReports.com: Alzheimer's Disease - Pipeline Review, H2 2013, New Report Launched

Alzheimer's Disease - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report also reviews key players involved in the therapeutic development for Alzheimer's Disease. Alzheimer's Disease - Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.

Scope

• A snapshot of the global therapeutic scenario for Alzheimer's Disease.
• A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Alzheimer's Disease pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 297 pages, 260 tables and 10 figures, “ Alzheimer's Disease - Pipeline Review, H2 2013 ” report provides information on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects.

In addition to covering the Alzheimer's Disease Overview, Late Stage Products, Mid Clinical Stage Products, Early Clinical Stage Products, Discovery and Pre-Clinical Stage Products, Companies Involved in Alzheimer's Disease Therapeutics Development, Alzheimer's Disease Therapeutics - Drug Profile Updates, Alzheimer's Disease Therapeutics - Discontinued Products, Alzheimer's Disease Therapeutics - Dormant Products. The report covers 170 companies; few are Bristol-Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Biogen Idec Inc., OXIS International, Inc., Shionogi & Co., Ltd., NsGene A/S, Amgen Inc., Sanofi-Aventis, AstraZeneca PLC, Eli Lilly and Company. Find all: Pharma and Healthcare Market Research Reports

MarketResearchReports.com: Acne And Related Disorders - Pipeline Review, H2 2013, New Report Launched

Acne And Related Disorders - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report also reviews key players involved in the therapeutic development for Acne And Related Disorders. Acne And Related Disorders - Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.

Scope

• A snapshot of the global therapeutic scenario for Acne And Related Disorders.
• A review of the Acne And Related Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Acne And Related Disorders pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Acne And Related Disorders.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Acne And Related Disorders pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 72 pages, 27 tables and 13 figures, “Acne And Related Disorders - Pipeline Review, H2 2013” report provides information on the therapeutic development for Acne And Related Disorders, complete with latest updates, and special features on late-stage and discontinued projects.

In addition to covering the Acne And Related Disorders Overview, Acne And Related Disorders Therapeutics under Development by Companies, Acne And Related Disorders Therapeutics under Investigation by Universities/Institutes, Mid Clinical Stage Products, Early Clinical Stage Products, Discovery and Pre-Clinical Stage Products, Companies Involved in Acne And Related Disorders Therapeutics Development, Acne And Related Disorders Therapeutics - Drug Profile Updates, Acne And Related Disorders Therapeutics - Dormant Products, Acne And Related Disorders - Product Development Milestones. The report covers 11 companies QLT Inc., Merz GmbH & Co. KGaA, Paratek Pharmaceuticals, Inc., Helix BioMedix, Inc., Phynova Group Ltd, Syntopix Group Plc, Novabiotics Ltd, Xenon Pharmaceuticals Inc., NovaLead Pharma Pvt. Ltd., Mimetica Pty Ltd. and Fibrocell Sciences, Inc.

Find all healthcare market research reports under a single page at: Healthcare Market Research Reports

MarketResearchReports.com: Contraception - Pipeline Review, H2 2013, New Report Launched

Contraception - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report also reviews key players involved in the therapeutic development for Contraception. Contraception - Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Contraception.
• A review of the Contraception products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Contraception pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Contraception.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 100 pages, 33 tables and 14 figures, “ Contraception - Pipeline Review, H2 2013 ” report provides information on the therapeutic development for Contraception, complete with latest updates, and special features on late-stage and discontinued projects.

In addition to covering the An Overview of Pipeline Products for Contraception, Contraception Therapeutics under Development by Companies, Contraception Therapeutics under Investigation by Universities/Institutes, Comparative Analysis, Contraception Therapeutics - Drug Profile Updates, Contraception Therapeutics - Discontinued Products, Contraception Therapeutics - Dormant Products and Contraception - Product Development Milestones. The report covers 17 companies Antares Pharma, Inc., Watson Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Limited, Bayer AG, TheraKine Inc., Ligand Pharmaceuticals Incorporated, Intas Pharmaceuticals Ltd., ANI Pharmaceuticals, Inc., HRA Pharma, SA, Pantarhei Bioscience BV, Hydra Biosciences, Inc., Agile Therapeutics, Inc., CG Therapeutics, Inc., Adamis Pharmaceuticals Corporation and CONRAD.

Find all healthcare market research reports under a single page at: Healthcare Market Research Reports

MarketResearchReports.com: Acute Coronary Syndrome - Pipeline Review, H2 2013, New Report Launched

Acute Coronary Syndrome - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report reviews key players involved in the therapeutic development for Acute Coronary Syndrome. Acute Coronary Syndrome Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Acute Coronary Syndrome.
• A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Acute Coronary Syndrome pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 114 pages, 31 tables and 12 figures, “Acute Coronary Syndrome - Pipeline Review, H2 2013” report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects.

In addition to covering the Acute Coronary Syndrome Overview, Late Stage Products, Mid Clinical Stage Products, Early Clinical Stage Products, Discovery and Pre-Clinical Stage Products, Acute Coronary Syndrome Therapeutics - Drug Profile Updates, Acute Coronary Syndrome Therapeutics - Discontinued Products, Acute Coronary Syndrome Therapeutics - Dormant Products, Acute Coronary Syndrome - Product Development Milestones. The report covers 17 companies F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline plc, Pfizer Inc., Bayer AG, Ligand Pharmaceuticals Incorporated, Medicure Inc., Arena Pharmaceuticals, Inc,. CSL Limited, LG Life Sciences, Ltd, Auspex Pharmaceuticals, Viron Therapeutics, Inc., Regado Biosciences, Cerenis Therapeutics SA Lacer, S.A., Lee's Pharmaceutical Holdings Limited and Ampio Pharmaceuticals, Inc.

Find all Diseases market research reports under a single page at: Diseases Market Research Reports

MarketResearchReports.com: Bone Metastasis - Pipeline Review, H2 2013, New Report Launched

Bone Metastasis Pipeline Review, H2 2013 , provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bone Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Metastasis. Bone Metastasis Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Bone Metastasis.
• A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Bone Metastasis pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Bone Metastasis.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

In addition to covering the Bone Metastasis Overview, An Overview of Pipeline Products for Bone Metastasis, Companies Involved in Bone Metastasis Therapeutics Development, Bone Metastasis Therapeutics - Drug Profile Updates, Bone Metastasis Therapeutics - Discontinued Products, Bone Metastasis Therapeutics - Dormant Products.  The report covers 18 companies Johnson & Johnson, Celsion Corporation, Amgen Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Bayer AG, Medivir AB, Osteologix, Inc., Transgene SA, Green Cross Corporation, Merrion Pharmaceuticals Plc, Digna Biotech, S.L., Debiopharm Group, Amura Holdings Ltd., Alethia Biotherapeutics Inc., Deciphera Pharmaceuticals, LLC, Targa Therapeutics Corp. and America Stem Cell, Inc.

Find all Diseases Market Research Reports  under a single page at: Diseases Market Research Reports

MarketResearchReports.com: EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022, New Report Launched

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of multifactorial origin that can affect any organ or organ systems, resulting in a broad spectrum of clinical manifestations ranging from dermatological involvement to multi-organ failure with episodes of relapses and remissions. The disease has unpredictable natural course and high rates of morbidity and death The incidence and prevalence of SLE varies globally and the variation is attributed to a combination of elements such as the characteristics of the population studied, sex, ethnicity, geographical locations, occupational factors, familial traits, time period involved, and the diagnostic criteria used. Lupus nephritis (LN) or lupus glomerulonephritis is a serious complication of SLE in which the kidneys are affected.

Publisher epidemiologists utilized data from country-specific studies published in peer-reviewed journals and governmental documents to provide the age- and sex-specific prevalent cases of diagnosed SLE in the respective markets. The forecast methodology and disease diagnosis criteria were consistent across all of the 7MM to allow for a meaningful comparison among them. The SLE prevalent case forecast followed the 1982 American College of Rheumatology classification and the LN cases were segmented according to the WHO 1982 classification. For more information visit: EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022

The report forecast that 2012 had 452,053 diagnosed prevalent cases of SLE in the 7MM, with approximately 60% of the diagnosed prevalent cases (265,562) in the US alone. Publisher epidemiologists forecast that there will be 488,769 diagnosed prevalent cases of SLE in the 7MM by 2022, with an overall average annual growth rate (AGR) of 0.81% during the forecast period. Publisher epidemiological forecast projected an increase in the diagnosed prevalent cases.

Scope

The Systemic Lupus Erythematosus (SLE) EpiCast Report provides an overview of the risk factors and global trends for SLE for the seven major markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan). GlobalData epidemiologists provide the 10-year epidemiological forecast of the diagnosed prevalent cases of SLE segmented by sex and age and the diagnosed prevalent cases of lupus nephritis (LN) for the 7MM. The prevalent cases of LN in the US, France, Germany, Italy, Spain, and UK are further segmented by severity class (Class I–VI).

The Systemic Lupus Erythematosus EpiCast report will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global SLE market.
• Quantify patient populations in the global SLE to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups, sex, and LN class that present the best opportunities for SLE therapeutics in each of the markets covered.
• Identify the percentage of LN prevalent cases in each severity class.

Spanning over 59 pages, 9 tables and 6 figures, “EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022” is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

In addition to covering the Epidemiology, Disease Background, Risk Factors and Comorbiditie, Global Trends, Forecast Methodology, Epidemiological Forecast of SLE (2012–2022), Discussion. Find all Healthcare Industry Reports under a single page at: Healthcare Market Research Reports